ARW ON RNA

Connecting the dots-GettyImages-1311926130 2 “Must-Haves” In mRNA CDMO Outsourcing Partnerships

In the final installment of this two-part series, Jain shares his assessment of the partnering landscape for mRNA therapeutic candidates. Though capacity has been a hot-button topic/need for other modalities in the ATMP space, his tips for evaluating CDMOs for mRNA therapeutics keep us aligned around the importance of capability and flexibility in outsourcing partnerships, especially when working with a nascent therapeutic modality.

OUR EXPERT NETWORK

MEET ARW

Anna Rose

I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.    

Start the conversation by following me on LinkedIn!

FREE EBOOK: MODERNA'S REGULATORY JOURNEY

This collection of articles tells the story of how Moderna brought one of the first mRNA vaccines to the market and has all the makings of a legend we will pass down through generations. However, unlike the legends of King Arthur or The Fountain of Youth, we can celebrate that Moderna’s legendary journey was — and still is — real.